Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule
The trial targets never-smoker non-small cell lung cancer (“NSCLC”) patients, a group with limited treatment options. Japan’s high incidence of never-smoker NSCLC makes it a strategic region for the trial. LP-300 is being tested alongside standard chemotherapy agents in patients who have relapsed after tyrosine kinase inhibitor therapy. Lantern's AI-driven approach may help identify and accelerate development of therapies in underserved cancer markets. Additional trial data from Taiwan and the U.S. is expected later in Q3 2025. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient…